Interview with Gerald Kolb, JD, president of The Breast Group in Bend, Ore. Kolb spoke at the 2016 AHRA meeting in Nashville about the challenges of multimodality breast screening, the need for more personalized screening programs and the impact of recent screening recommendations. Read about the lastest advances in breast imaging.

Views

Recent Videos View all 642 items

Artificial Intelligence | August 18, 2022

Digital solutions like AI and the cloud are driving innovation and transforming the way radiologists and imaging centers approach their work. ITN recently spoke with Alexandre Salvador, vice president and global head of digital business solutions for Bayer's radiology business, about Calantic Digital Solutions, Bayer's new cloud-based platform providing AI applications integrated into the clinical workflow of the radiology department. 

Proton Therapy | May 16, 2022

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal investigator of the FAST-01 trial, explains FLASH therapy and details on the trial. This study is testing the use of a single FLASH proton therapy session, rather than weeks of fractionated doses.

FLASH and hypo fractionated therapy have been among the hottest topics in radiation oncology. The premise of FLASH is to deliver extremely high doses of radiation to a tumor in one, short dose. Lab testing has shown this actually has a healthy tissue sparing capability and may help in reducing collateral damage.  

If this and other trials show benefit and improved outcomes from FLASH, it is possible this may become the primary treatment method for many cancers in the years to come. Reducing therapy to one treatment session also would open up much more time for proton centers so many more patients could be treated. It also would be a significant time and cost savings for patients and their families, who would not be required to stay at nearby hotels for extended stays during their course of treatment.  

Cincinnati Children's/UC Health Proton Therapy Center announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) in October. This is the first human clinical trial of FLASH therapy, which centered on patients with metastases in arms and legs to avoid irradiating critical structures. If this trials shows benefits and low toxicity, followup studies will attempt more complex treatments in other parts of the body.

Related ASTRO 2021 Radiation Oncology Content:

7 Trends in Radiation Therapy at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021 

Photo Gallery of Technologies at ASTRO 2021

VIDEO: Sedating Children With Movies Rather Than Drugs for Radiation Therapy — Interview with Jeffrey T. Chapman

VIDEO: 4 Radiation Oncology Technologies to Watch — Interview with Anthony Zietman, M.D.

VIDEO: Advances in Radiopharmaceutical Therapy — Interview with Ana Kiess, M.D., Ph.D.

VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare — Interview with Walter Curran, Jr. M.D., 

VIDEO: Elekta Harmony Radiotherapy System Walk-around

VIDEO Example of the Varian Noona Bidirection Oncology Patient Interface Software

VIDEO: Examples of Cherenkov Radiation Imaging During Radiation Therapy

Find more radiation oncology technology news

Point-of-Care Ultrasound (POCUS) | May 13, 2022

Arun Nagdev, M.D., director of emergency ultrasound at the Alameda Health System, clinical associate professor, University of California San Francisco (UCSF) School of Medicine, and incoming president for the American College of Emergency Physicians (ACEP) ultrasound section, explains the rise in point-of-care ultrasound (POCUS) since the start of the COVID-19 pandemic. Nagdev has used cart-based and several hand-held systems to the emergency department to triage patients, help sort out COVID and non-COVID patients and identify patients that need more detailed radiology imaging or with issues that need immediate attention, such as pulmonary embolism, heart attacks and aortic aneurisms. 

Nagdev also serves as senior director of clinical education for start-up POCUS company Exo, which is developing a new chip-based, handheld ultrasound system with a high definition transducer.

Watch the related VIDEO: How to Image COVID-19 and Radiological Presentations of the Virus — Interview with Margarita Revzin, M.D.

More COVID-19 content can be found here

Sponsored Videos View all 171 items

Artificial Intelligence | August 18, 2022

Digital solutions like AI and the cloud are driving innovation and transforming the way radiologists and imaging centers approach their work. ITN recently spoke with Alexandre Salvador, vice president and global head of digital business solutions for Bayer's radiology business, about Calantic Digital Solutions, Bayer's new cloud-based platform providing AI applications integrated into the clinical workflow of the radiology department. 

PACS | March 14, 2022

Software automation can help improve many processes, including verifying eligibility for patient exams, navigating the patient responsibility landscape, and meeting the upcoming CDSM mandate for Appropriate Use CriteriaITN recently spoke with with Kevin Borden, Vice President of Product, HCIT, for Konica Minolta Healthcare Americas about how Konica Minolta is leveraging automation to enhance productivity and efficiency in these areas. 

Related content:

New Exa Platform Functionality Automates Decision Support, Insurance-Related Tasks for Enhanced Productivity and Profitability

More HIMSS 2022 content

Computed Tomography (CT) | March 09, 2022

At RSNA 2021, Philips highlighted the launch of two new innovative CT systems – the multi-energy Spectral CT 7500 and the CT 5100 Incisive with embedded AI capabilities. ITN spoke with Wendy Winkle Lawless, CT Business Market Leader - North America, Philips, to learn more about these new systems.

Contrast Media | February 23, 2022

With the use of contrast agents and radiotracers on the rise, GE Healthcare has seen increases in demand across their pharmaceutical diagnostics business. At RSNA 2021, Marco Campione, General Manager, Pharmaceutical Diagnostics Americas, GE Healthcare, shared how recent investments are helping to meet this increased demand.

Find more RSNA21 content here

Technology Reports View all 12 items

Artificial Intelligence | July 22, 2021

This is an overview of trends and technologies in radiology artificial intelligence (AI) applications in 2021. Views were shared by 11 radiologists using AI and industry leaders, which include:

Randy Hicks, M.D., MBA, radiologist and CEO of Reginal Medical Imaging (RMI), and an iCAD Profound AI user.

• Prof. Dr. Thomas Frauenfelder, University of Zurich, Institute for Diagnostic and Interventional Radiology, and Riverain AI user. 

• Amy Patel, M.D., medical director of Liberty Hospital Women’s Imaging, assistant professor of radiology at UMKC, and user of Kios AI for breast ultrasound. 

Sham Sokka, Ph.D., vice president and head of innovation, precision diagnosis, Philips Healthcare.

Ivo Dreisser, Siemens Healthineers, global marketing manager for the AI Rad Companion.

Bill Lacey, vice president of medical informatics, Fujifilm Medical Systems USA.

• Karley Yoder, vice president and general manager, artificial intelligence, GE Healthcare.

Georges Espada, head of Agfa Healthcare digital and computed radiography business unit.

Pooja Rao, head of research and development and co-founder of Qure.ai.

Jill Hamman, world-wide marketing manager at Carestream Health.

Sebastian Nickel, Siemens Healthineers, global product manager for the AI Pathway Companion. 

There has been a change in attitudes about AI on the expo floor at the Radiological Society of North America (RSNA) over the last two years. AI conversations were originally 101 level and discussed how AI technology could be trained to sort photos of dogs and cats. However, in 2020, with numerous FDA approvals for various AI applications, the conversations at RSNA, and industry wide, have shifted to that of accepting the validity of AI. Radiologists now want to discuss how a specific AI algorithm is going to help them save time, make more accurate diagnoses and make them more efficient.

With a higher level of maturity in AI and the technology seeing wider adoption, radiologists using it say AI gives them additional confidence in their diagnoses, and can even help readers who may not be deep experts in the exam type they are being asked to read. 

With a myriad of new AI apps gaining regulatory approval from scores of imaging vendors, the biggest challenge for getting this technology into hospitals is an easy to integrate format. This has led to several vendors creating AI app stores. These allow AI apps to integrate easily into radiology workflows because the apps are already integrated as third-party software into a larger radiology vendors' IT platform.  

There are now hundreds of AI applications that do a wide variety of analysis, from data analytics, image reconstruction, disease and anatomy identification, automating measurements and advanced visualization. The AI applications can be divided into 2 basic types — AI to improve workflow, and AI for clinical decision support, such as diagnostic aids.

On the workflow side, several vendors are leveraging AI to pull together all of a patients' information, prior exams and reports in one location and to digest the information so it is easier for the radiologist to consume. Often the AI pulls only data and priors that relate to a specific question being asked, based on the imaging protocol used for the exam. One example of this is the Siemens Healthineers AI Clinical Pathway and Siemens AI integrations with PACS to automate measurements and advanced visualization.

AI is also helping simplify complex tasks and help reduce the reading time on involved exams. One example of this is in 3-D breast tomosythesis with hundreds of images, which is rapidly replacing 2-D mammography, which only produces 4 images. Another example is automated image reconstruction algorithms to significantly reduce manual work. AI also is now being integrated directly into several vendors' imaging systems to speed workflow and improve image quality.

Vendors say AI is here to stay. They explain the future of AI will be automation to help improve image quality, simplify manual processes, improved diagnostic quality, new ways to analyze data, and workflow aids that operate in the background as part of a growing number of software solutions. 

Several vendors at RSNA 2020 noted that AI's biggest impact in the coming years will be its ability to augment and speed the workflow for the small number of radiologists compared to the quickly growing elder patient populations worldwide. There also are applications in rural and developing countries were there are very low numbers of physicians or specialists.

 

Related AI in Medical Imaging Content:

AI Outperforms Humans in Creating Cancer Treatments, But Do Doctors Trust It?

VIDEO: Artificial Intelligence For MRI Helps Overcome Backlog of Exams Due to COVID

How AI is Helping the Fight Against Breast Cancer

VIDEO: Use of Artificial Intelligence in Nuclear Imaging

3 High-impact AI Market Trends in Radiology at RSNA 2019

 

Photo Gallery of New Imaging Technologies at RSNA 2019

VIDEO: Editors Choice of the Most Innovative New Radiology Technology at RSNA 2019

Study Reveals New Comprehensive AI Chest X-ray Solution Improves Radiologist Accuracy

VIDEO: Real-world Use of AI to Detect Hemorrhagic Stroke

The Radiology AI Evolution at RSNA 2019

 

Eliminating Bias from Healthcare AI Critical to Improve Health Equity

VIDEO: FDA Cleared Artificial Intelligence for Immediate Results of Head CT Scans

Building the Future of AI Through Data

WEBINAR: Do More, Perform Better: Delivering Clinical Quality through Advanced Radiology and Artificial Intelligence

Integrating Artificial Intelligence in Treatment Planning

 

Selecting an AI Marketplace for Radiology: Key Considerations for Healthcare Providers

Artificial Intelligence Improves Accuracy of Breast Ultrasound Diagnoses

Artificial Intelligence Greatly Speeds Radiation Therapy Treatment Planning

WEBINAR: Building the Bridge - How Imaging AI is Delivering Clinical Value Across the Care Continuum

AI in Medical Imaging Market to Reach $1.5B by 2024

 

VIDEO: AI-Assisted Automatic Ejection Fraction for Point-of-Care Ultrasound

5 Trends in Enterprise Imaging and PACS Systems

VIDEO: Artificial Intelligence to Automate CT Calcium Scoring and Radiomics

Scale AI in Imaging Now for the Post-COVID Era

VIDEO: Integrating Artificial Intelligence Into Radiologists Workflow

 

Northwestern Medicine Introduces Artificial Intelligence to Improve Ultrasound Imaging

Find more artificial intelligence news and video

 

 

 

Artificial Intelligence | February 21, 2020

In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intelligence (AI) advances at the Radiological Society of North America (RSNA) 2019 annual meeting.

Enterprise Imaging | February 21, 2020

In Enterprise Imaging at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of enterprise imaging advances at the Radiological Society of North America (RSNA) 2019 annual meeting.

Radiation Oncology View all 137 items

Proton Therapy | May 16, 2022

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal investigator of the FAST-01 trial, explains FLASH therapy and details on the trial. This study is testing the use of a single FLASH proton therapy session, rather than weeks of fractionated doses.

FLASH and hypo fractionated therapy have been among the hottest topics in radiation oncology. The premise of FLASH is to deliver extremely high doses of radiation to a tumor in one, short dose. Lab testing has shown this actually has a healthy tissue sparing capability and may help in reducing collateral damage.  

If this and other trials show benefit and improved outcomes from FLASH, it is possible this may become the primary treatment method for many cancers in the years to come. Reducing therapy to one treatment session also would open up much more time for proton centers so many more patients could be treated. It also would be a significant time and cost savings for patients and their families, who would not be required to stay at nearby hotels for extended stays during their course of treatment.  

Cincinnati Children's/UC Health Proton Therapy Center announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) in October. This is the first human clinical trial of FLASH therapy, which centered on patients with metastases in arms and legs to avoid irradiating critical structures. If this trials shows benefits and low toxicity, followup studies will attempt more complex treatments in other parts of the body.

Related ASTRO 2021 Radiation Oncology Content:

7 Trends in Radiation Therapy at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021 

Photo Gallery of Technologies at ASTRO 2021

VIDEO: Sedating Children With Movies Rather Than Drugs for Radiation Therapy — Interview with Jeffrey T. Chapman

VIDEO: 4 Radiation Oncology Technologies to Watch — Interview with Anthony Zietman, M.D.

VIDEO: Advances in Radiopharmaceutical Therapy — Interview with Ana Kiess, M.D., Ph.D.

VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare — Interview with Walter Curran, Jr. M.D., 

VIDEO: Elekta Harmony Radiotherapy System Walk-around

VIDEO Example of the Varian Noona Bidirection Oncology Patient Interface Software

VIDEO: Examples of Cherenkov Radiation Imaging During Radiation Therapy

Find more radiation oncology technology news

Radiation Therapy | February 16, 2022

Elekta’s latest linear accelerator, Harmony, is designed to provide a productive and versatile radiotherapy solution for both mature and developing markets. ITN recently spoke with Chris Gilpin, Global Product Marketing Manager, and Emily Basset, Global Clinical Marketing Manager, to learn more about the treatment system. 

Related content:

Growing Use of Nuclear Medicine and Radiation Therapy for Diagnosis and Treatment

7 Trends in Radiation Therapy at ASTRO 2021

VIDEO: Elekta Harmony Radiotherapy System Walk-around

Photo Gallery of Technologies at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021

Find more radiation oncology technology news

Radiation Therapy | February 02, 2022

Magdalena Bazalova-Carter, Ph.D., assistant professor, University of Victoria University, discusses the current state of ultra-high dose FLASH radiation therapy at the 2021 American Society of Radiation Oncology (ASTRO) annual meeting. Flash therapy is said to be a key technology to keep an eye on in the next few years. If it proves viable in human patients, it promises to greatly shorten treatment times, and reduce fractions to between 1-3 sessions.

The idea is that a super-high dose of radiation is delivered in one large, very fast dose. It appears that despite the high dose of radiation, there is a tissue sparing biology mechanism that is not yet fully understood, where health tissue is preserved and there is less collateral damage than the standard series of lower dose fractions over days or weeks.  

Flash therapy is being tested in electron beam therapy systems to treat superficial cancers, which are much easier to adopt to flash than deeper tissue tumors. Proton may be able to produce the higher energies needed for deeper tumor treatments, but current photon beam systems are limited because to deliver the high doses needed may cause enough heat to melt the X-ray beam source.

7 Trends in Radiation Therapy at ASTRO 2021

Photo Gallery of Technologies at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021

Find more radiation oncology technology news

Radiology Imaging View all 386 items

Point-of-Care Ultrasound (POCUS) | May 13, 2022

Arun Nagdev, M.D., director of emergency ultrasound at the Alameda Health System, clinical associate professor, University of California San Francisco (UCSF) School of Medicine, and incoming president for the American College of Emergency Physicians (ACEP) ultrasound section, explains the rise in point-of-care ultrasound (POCUS) since the start of the COVID-19 pandemic. Nagdev has used cart-based and several hand-held systems to the emergency department to triage patients, help sort out COVID and non-COVID patients and identify patients that need more detailed radiology imaging or with issues that need immediate attention, such as pulmonary embolism, heart attacks and aortic aneurisms. 

Nagdev also serves as senior director of clinical education for start-up POCUS company Exo, which is developing a new chip-based, handheld ultrasound system with a high definition transducer.

Watch the related VIDEO: How to Image COVID-19 and Radiological Presentations of the Virus — Interview with Margarita Revzin, M.D.

More COVID-19 content can be found here

Computed Tomography (CT) | March 09, 2022

At RSNA 2021, Philips highlighted the launch of two new innovative CT systems – the multi-energy Spectral CT 7500 and the CT 5100 Incisive with embedded AI capabilities. ITN spoke with Wendy Winkle Lawless, CT Business Market Leader - North America, Philips, to learn more about these new systems.

Digital Radiography (DR) | March 01, 2022

At RSNA 2021, Konica Minolta introduced the mKDR Xpress Mobile X-ray system and the Aero DR Carbon flat panel detector. Also on display was nVoq’s cloud-based speech recognition and automation solution and new features for the Exa platform that automate common clinical and administrative tasks.

You can find more RSNA21 content here

Molecular Imaging View all 33 items

Computed Tomography (CT) | March 09, 2022

At RSNA 2021, Philips highlighted the launch of two new innovative CT systems – the multi-energy Spectral CT 7500 and the CT 5100 Incisive with embedded AI capabilities. ITN spoke with Wendy Winkle Lawless, CT Business Market Leader - North America, Philips, to learn more about these new systems.

Radiopharmaceuticals and Tracers | November 17, 2021

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins University, explains the current state of patient-centered radiopharmaceutical therapy at the American Society of Radiation Oncology (ASTRO) 2021 meeting. 

She discusses development and use over the past decade of Radium-223 dichloride and Lutetium-177 dotatate. Kiess also expects there will be targeted injectable radiopharmaceuticals for nearly all solid tumor types in the next decade. She said her center is currently investigating the use of radiopharma agents to treat oligometastatic metastatic cancers.

Photo Gallery of Technologies at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021

Find more radiation oncology technology news

Radiation Oncology | November 16, 2021

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are helping advance radiation oncology care during the American Society of Radiation Oncology (ASTRO) 2021 meeting. These technology advances include:

   • Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging for prostate cancer.

   • MRI-linear accelerator (Linac) systems that allow real-time imaging during radiation therapy.

   • Remote treatment planning to help radiation treatment centers that are in rural areas.

Prostate cancer is one of the most common cancers in men. The new PSMA PET imaging is expected to significantly improve how prostate cancer is detected and treated. The FDA approved the drug for PET nuclear imaging of PSMA-positive lesions in men with prostate cancer. 68Ga-PSMA-11 is a radioactive imaging agent that binds to prostate cancer cells to help localize prostate cancer cells.

Photo Gallery of Technologies at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021

Find more radiation oncology technology news

Coronavirus (COVID-19) | May 11, 2021

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a recent study that showed COVID-19 (SARS-CoV-2) vaccine adenopathy can persist more than 6 weeks. This swelling of lymph nodes is similar to what is seen cancer and infections and the new findings show it can last longer than 7-10 weeks. The current recommended time people should delay medical imaging is 6 weeks after receiving a COVID vaccine to avoid a misdiagnosis,[2] but this new study shows there is increased inflammation shown on PET-CT imaging for much longer.

These were the findings in the Radiology published study "Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination."[1]

Researchers using fluorodeoxyglucose (FDG)-positron emission tomography (PET) have found increased FDG uptake in the lymph nodes of patients 7-10 weeks past their second mRNA-based Pfizer-BioNTech COVID-19 vaccination. This new information indicates a persistent immune response that could be mistaken on imaging exams for serious conditions like lymphoma over a much longer period of time.

Recent recommendations for post-vaccine lymphadenopathy advise scheduling routine imaging, such as screening mammography, before, or at least 6 weeks after, the final vaccination dose to eliminate false positive results. However, this new research showed that avid axillary lymph node uptake was present beyond 6 weeks after the second vaccination in more than 29% of the patients in the study cohort.

The authors stated “This study shows that avid axillary lymph node uptake on FDG PET/CT can be detected in more than a quarter of our patient population even beyond 6 weeks after the second dose of the mRNA-based COVID-19 vaccination. Compared to a previous study showing normalization of FDG uptake within 40 days of receiving an inactivated H1N1 influenza vaccine, we found uptake persistence even at 70 days. Physicians should be aware of this potential pitfall.”

Some images in this video are from another Radiology study, which showed PET tracer uptake at the COVID vaccine injection site and other examples of axillary adenopathy.[3]

 

Related COVID Vaccine Axillary Adenapathy Content:

COVID-19 Vaccine Can Cause False Positive Cancer Diagnosis

Help Spread Awareness of Potential COVID-19 Vaccine Imaging Side-effects

VIDEO: COVID Vaccine May Cause Enlarged Lymph Nodes on Mammograms — Interview with Constance "Connie" Lehman, M.D.

COVID-19 Vaccination Axillary Adenopathy Detected During Breast Imaging

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4

Find more radiology related COVID content 

References:

1. Yael Eshet, Noam Tau1, Yousef Alhoubani, Nayroz Kanana, Liran Domachevsky, Michal Eifer. Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination. Radiology. Published Online:Apr 27 2021https://doi.org/10.1148/radiol.2021210886.

2. Constance D. Lehman, Leslie R. Lamb, and Helen Anne D'Alessandro. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach American Journal of Roentgenology. 10.2214/AJR.21.25688.

3. Can Özütemiz, Luke A. Krystosek, An L. Church, Anil Chauhan, Jutta M. Ellermann, Evidio Domingo-Musibay, Daniel Steinberger. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients. Radiology. Published Online:Feb 24 2021https://doi.org/10.1148/radiol.2021210275.

 

Conference Coverage View all 515 items

Proton Therapy | May 16, 2022

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal investigator of the FAST-01 trial, explains FLASH therapy and details on the trial. This study is testing the use of a single FLASH proton therapy session, rather than weeks of fractionated doses.

FLASH and hypo fractionated therapy have been among the hottest topics in radiation oncology. The premise of FLASH is to deliver extremely high doses of radiation to a tumor in one, short dose. Lab testing has shown this actually has a healthy tissue sparing capability and may help in reducing collateral damage.  

If this and other trials show benefit and improved outcomes from FLASH, it is possible this may become the primary treatment method for many cancers in the years to come. Reducing therapy to one treatment session also would open up much more time for proton centers so many more patients could be treated. It also would be a significant time and cost savings for patients and their families, who would not be required to stay at nearby hotels for extended stays during their course of treatment.  

Cincinnati Children's/UC Health Proton Therapy Center announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) in October. This is the first human clinical trial of FLASH therapy, which centered on patients with metastases in arms and legs to avoid irradiating critical structures. If this trials shows benefits and low toxicity, followup studies will attempt more complex treatments in other parts of the body.

Related ASTRO 2021 Radiation Oncology Content:

7 Trends in Radiation Therapy at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021 

Photo Gallery of Technologies at ASTRO 2021

VIDEO: Sedating Children With Movies Rather Than Drugs for Radiation Therapy — Interview with Jeffrey T. Chapman

VIDEO: 4 Radiation Oncology Technologies to Watch — Interview with Anthony Zietman, M.D.

VIDEO: Advances in Radiopharmaceutical Therapy — Interview with Ana Kiess, M.D., Ph.D.

VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare — Interview with Walter Curran, Jr. M.D., 

VIDEO: Elekta Harmony Radiotherapy System Walk-around

VIDEO Example of the Varian Noona Bidirection Oncology Patient Interface Software

VIDEO: Examples of Cherenkov Radiation Imaging During Radiation Therapy

Find more radiation oncology technology news

PACS | March 14, 2022

Software automation can help improve many processes, including verifying eligibility for patient exams, navigating the patient responsibility landscape, and meeting the upcoming CDSM mandate for Appropriate Use CriteriaITN recently spoke with with Kevin Borden, Vice President of Product, HCIT, for Konica Minolta Healthcare Americas about how Konica Minolta is leveraging automation to enhance productivity and efficiency in these areas. 

Related content:

New Exa Platform Functionality Automates Decision Support, Insurance-Related Tasks for Enhanced Productivity and Profitability

More HIMSS 2022 content

Computed Tomography (CT) | March 09, 2022

At RSNA 2021, Philips highlighted the launch of two new innovative CT systems – the multi-energy Spectral CT 7500 and the CT 5100 Incisive with embedded AI capabilities. ITN spoke with Wendy Winkle Lawless, CT Business Market Leader - North America, Philips, to learn more about these new systems.

Information Technology View all 281 items

Artificial Intelligence | August 18, 2022

Digital solutions like AI and the cloud are driving innovation and transforming the way radiologists and imaging centers approach their work. ITN recently spoke with Alexandre Salvador, vice president and global head of digital business solutions for Bayer's radiology business, about Calantic Digital Solutions, Bayer's new cloud-based platform providing AI applications integrated into the clinical workflow of the radiology department. 

PACS | March 14, 2022

Software automation can help improve many processes, including verifying eligibility for patient exams, navigating the patient responsibility landscape, and meeting the upcoming CDSM mandate for Appropriate Use CriteriaITN recently spoke with with Kevin Borden, Vice President of Product, HCIT, for Konica Minolta Healthcare Americas about how Konica Minolta is leveraging automation to enhance productivity and efficiency in these areas. 

Related content:

New Exa Platform Functionality Automates Decision Support, Insurance-Related Tasks for Enhanced Productivity and Profitability

More HIMSS 2022 content

Radiation Oncology | February 02, 2022

Douglas E. Holt, M.D., a radiation oncologist at Eastern Idaho Regional Medical Center, explains the use of 3-D virtual reality volumetric imaging review to help improve cancer patients’ understanding of their disease and treatment. Pictures are worth a thousand words, and moving pictures inside a patient's body even more. Holt said using virtual reality to go through the patient's anatomy in 3D and to show them what is wrong and how it will be treated offers a new level of understanding that is not possible using a discussion or a couple still images from their medical imaging.

Holt presented this study as a late-breaker at the 2021 American Society of Radiation Oncology (ASTRO) annual meeting.

Find more ASTRO videos and news

7 Trends in Radiation Therapy at ASTRO 2021

Photo Gallery of Technologies at ASTRO 2021

Radiation Oncology Research Featured at ASTRO 2021

Find more radiation oncology technology news

Enterprise Imaging | January 27, 2022

Rik Primo, principle at Primo Medical Imaging Informatics Consultants and former health IT developer with Siemens, Philips and Agfa, explains the difference cloud-native versus cloud-enabled PACS and radiology enterprise imaging systems. He spoke with ITN during RSNA 2021.the Radiological Society of North America (RSNA) 2021 annual meeting.

Find more RSNA news and video

Related content on enterprise imaging

 

Women's Health View all 79 items

Breast Imaging | December 13, 2021

Stamatia Destounis, M.D., FACR, chief of the American College of Radiology (ACR) Breast Commission, managing partner, Elizabeth Wende Breast Care, Rochester, N.Y., explains some of the key trends in breast imaging at the 2021  Radiological Society of North America (RSNA) meeting.

She discusses the trends of 3D mammography seeing rapid growth, adoption of synthetic 2D breast images from the tomosynthesis datasets, contrast-enhanced mammography, and breast MRI to help women with dense breast tissue. Destounis also discusses the use of artificial intelligence (AI) to help radiologists with finding what they needs with larger datasets in 3D mammography, and to help act as a second set of eyes.

Early in 2021, with the roll out of the COVID vaccines, one of the biggest headlines in radiology was that the vaccine can show false positives for cancer because it may cause inflammation of lymph nodes. Destounis explains this issue and how women's health centers have largely overcome this by asking patients about their vaccination status and planning imaging around the vaccination dates.

Related Breast Imaging Content:

COVID-19 Vaccine Can Cause False Positive Cancer Diagnosis

Help Spread Awareness of Potential COVID-19 Vaccine Imaging Side-effects

VIDEO: COVID Vaccine May Cause Enlarged Lymph Nodes on Mammograms — Interview with Constance "Connie" Lehman, M.D.

COVID-19 Vaccination Axillary Adenopathy Detected During Breast Imaging

VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks — Interview with Yael Eshet, M.D.

VIDEO: Artificial Intelligence Trends in Medical Imaging — Interview with Signify Research

Technology Report: Artificial Intelligence in Radiology 2021

Find more RSNA news and video

Coronavirus (COVID-19) | May 11, 2021

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a recent study that showed COVID-19 (SARS-CoV-2) vaccine adenopathy can persist more than 6 weeks. This swelling of lymph nodes is similar to what is seen cancer and infections and the new findings show it can last longer than 7-10 weeks. The current recommended time people should delay medical imaging is 6 weeks after receiving a COVID vaccine to avoid a misdiagnosis,[2] but this new study shows there is increased inflammation shown on PET-CT imaging for much longer.

These were the findings in the Radiology published study "Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination."[1]

Researchers using fluorodeoxyglucose (FDG)-positron emission tomography (PET) have found increased FDG uptake in the lymph nodes of patients 7-10 weeks past their second mRNA-based Pfizer-BioNTech COVID-19 vaccination. This new information indicates a persistent immune response that could be mistaken on imaging exams for serious conditions like lymphoma over a much longer period of time.

Recent recommendations for post-vaccine lymphadenopathy advise scheduling routine imaging, such as screening mammography, before, or at least 6 weeks after, the final vaccination dose to eliminate false positive results. However, this new research showed that avid axillary lymph node uptake was present beyond 6 weeks after the second vaccination in more than 29% of the patients in the study cohort.

The authors stated “This study shows that avid axillary lymph node uptake on FDG PET/CT can be detected in more than a quarter of our patient population even beyond 6 weeks after the second dose of the mRNA-based COVID-19 vaccination. Compared to a previous study showing normalization of FDG uptake within 40 days of receiving an inactivated H1N1 influenza vaccine, we found uptake persistence even at 70 days. Physicians should be aware of this potential pitfall.”

Some images in this video are from another Radiology study, which showed PET tracer uptake at the COVID vaccine injection site and other examples of axillary adenopathy.[3]

 

Related COVID Vaccine Axillary Adenapathy Content:

COVID-19 Vaccine Can Cause False Positive Cancer Diagnosis

Help Spread Awareness of Potential COVID-19 Vaccine Imaging Side-effects

VIDEO: COVID Vaccine May Cause Enlarged Lymph Nodes on Mammograms — Interview with Constance "Connie" Lehman, M.D.

COVID-19 Vaccination Axillary Adenopathy Detected During Breast Imaging

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4

Find more radiology related COVID content 

References:

1. Yael Eshet, Noam Tau1, Yousef Alhoubani, Nayroz Kanana, Liran Domachevsky, Michal Eifer. Prevalence of Increased FDG PET/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination. Radiology. Published Online:Apr 27 2021https://doi.org/10.1148/radiol.2021210886.

2. Constance D. Lehman, Leslie R. Lamb, and Helen Anne D'Alessandro. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach American Journal of Roentgenology. 10.2214/AJR.21.25688.

3. Can Özütemiz, Luke A. Krystosek, An L. Church, Anil Chauhan, Jutta M. Ellermann, Evidio Domingo-Musibay, Daniel Steinberger. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients. Radiology. Published Online:Feb 24 2021https://doi.org/10.1148/radiol.2021210275.

 

Breast Imaging | March 26, 2021

Constance "Connie" Lehman, M.D., Ph.D., chief of breast imaging, co-director of the Avon Comprehensive Breast Evaluation Center at the Massachusetts General Hospital, and professor of radiology at Harvard Medical School, explains issues and suggested guidelines for women who receive the COVID-19 vaccine and need to get a mammogram. In the first three months since the vaccines have been released, there have been numerous case reports of the vaccine causing swollen lymph nodes. This is would usually raise a red flag for breast cancer, but is normal for many women receiving the vaccine as their body's immune system gears up against the virus. 

Lehman said cases reports of axillary adenopathy have been identified on breast imaging after coronavirus disease (COVID-19) vaccination and are rising. Lehman et al. proposed a pragmatic management approach in a recent article in the American Journal of Roentgenology (AJR).[1]

In the settings of screening mammography, screening MRI and diagnostic imaging work-up of breast symptoms, with no imaging findings beyond unilateral axillary adenopathy ipsilateral to recent (prior six weeks) vaccination, they report the adenopathy as benign with no further imaging indicated if no nodes are palpable six weeks after the last vaccine dose. 

For patients with palpable axillary adenopathy in the setting of ipsilateral recent vaccination, clinical follow-up of the axilla is recommended. In all these scenarios, axillary ultrasound is recommended if clinical concern persists six weeks after vaccination. 

In patients with recent breast cancer diagnosis in the pre- or peri-treatment setting, prompt recommended imaging is encouraged as well as vaccination (in the thigh or contralateral arm). The recommendations align with the ACR BI-RADS Atlas and aim to: 1) reduce patient anxiety, provider burden, and costs of unnecessary evaluation of enlarged nodes in the setting of recent vaccination, and 2) avoid further delays in vaccinations and breast cancer screening during the pandemic.

 

Related Medical Imaging of COVID Content:

COVID-19 Vaccination Axillary Adenopathy Detected During Breast Imaging

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS) — Interview with Mike Stone, M.D.

VIDEO: Use of Teleradiology During the COVID-19 Pandemic — Interview with John Kim, M.D.

Find more radiology related COVID content 

 

Reference:

1. Constance D. Lehman, Leslie R. Lamb, and Helen Anne D'Alessandro. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach American Journal of Roentgenology. 10.2214/AJR.21.25688

 

 

Subscribe Now